Agomab Therapeutics raised €21M in a Series A round in Apr 2019. The company is based in Ghent, Belgium. Investors in the round: Advent France Biotechnology, V-Bio Ventures. Data as of 6 Aug 2026.
Reported in EUR — no conversion. €21M
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
